** Shares of cancer therapy developer Theriva Biologics TOVX.A rise 80% to $2.45 premarket
** Co says its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial
** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX
** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body
** Co says the drug has been tested in over 140 patients and was well-tolerated
** As of last close, stock down 22.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.